A Clinical Study of Tranilast in the Treatment of Mucinoses

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03490708

Enrollment

Registered

2018-04-06

Start date

2018-04-30

Completion date

2022-12-31

Last updated

2018-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucinoses

Keywords

Mucinoses, Tranilast

Brief summary

56 participants with Mucinoses will be selected to receive treatment of tranilast. After a period of time ,the investigators can determine the efficacy of the drug by detecting the the thickness and area of skin before and after treatment.

Detailed description

56 participants with Mucinoses will be selected. After the signing of the informed consent ,participants will be collected the initial lesions photos,the thickness and area of skin lesions by ultrasound and magnetic resonance,and chemical examinations including blood routine examination, routine urine test, liver function, renal function. During tranilast (0.1g each time, three times a day,12 months) treatment, participants need regular follow-up (1 per month) including liver and kidney function, blood glucose level monitoring, and every three months to retest lesion thickness and area. With 3 month as a time point, participants were observed for four points. After the experiment, the experimental data will be arranged and the data of the thickness and area change of skin lesions will be statistically processed to determine whether it is meaningful.

Interventions

DRUGTranilast

Subjects will be treated with tranilast

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Clinical and histopathological examination has been proved to be Mucinoses; 2. Ultrasound and magnetic resonance detection found that the skin was thickened.

Exclusion criteria

1. With a liver or kidney disease, or accompanied by a severe infection; 2. Poor control of primary disease; 3. With mental disease.

Design outcomes

Primary

Measure	Time frame	Description
Measure the volume change of skin lesions by ultrasound	This experiment will last for 12 months	During tranilast (0.1g each time, three times a day, 12 months) treatment, patients need to test lesion volume.The reduction of volume greater than 50% is judged to be effective

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026